Table 2.
Treatment details and outcomes
| Plaque type | Apex dose, Gy | Treatment duration, h | BCVA | Height, mm | Diameter, mm | Complications | Reccurence | Follow-up duration, months | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| pre | post | pre | post | pre | post | |||||||
| 1 | COB | 50 | 72 | 0.05 | 0.9 | 3.35 | 2.77 | 6.6 | 4.9 | No | No | 6 |
| 2 | CCB | 50 | 72 | CF50 | 0.8 | 4.02 | Flat | 10.5 | Flat | No | No | 16 |
| 3 | COB | 50 | 72 | HM | 0.3 | 3.71 | 2.44 | 8.08 | 7.47 | No | No | 10 |
| 4 | COB | 50 | 144 | HM | 0.2 | 7.57 | Flat | 12.59 | Flat | No | No | 9 |
| 5 | COB | 50 | 144 | HM | 0.1 | 7.03 | 2.40 | 12.11 | 10.29 | No | No | 24 |
| 6 | COB | 50 | 48 | 0.1 | 0.8 | 3.53 | 2.57 | 5.58 | 4.07 | No | No | 15 |
| 7 | CCB | 50 | 34 | 0.05 | 0.4 | 4.09 | 1.78 | 8.43 | 5.58 | No | No | 8 |
BCVA, best corrected visual acuity; Gy, Gray.